How to buy Noxopharm (NOX) shares

Learn how to easily invest in Noxopharm shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Noxopharm Limited is a biotechnology business based in Australia. Noxopharm shares (NOX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Noxopharm has a trailing 12-month revenue of around $5.6 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Noxopharm

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Noxopharm . Find the share by name or ticker symbol: NOX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Noxopharm reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Noxopharm . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Noxopharm stock price (ASX:NOX)

Use our graph to track the performance of NOX stocks over time.

Noxopharm shares at a glance

Information last updated 2021-11-27.
52-week range$0.41 - $0.99
50-day moving average $0.5186
200-day moving average $0.5947
Target price$1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.035

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
ASX shares, US shares
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
ThinkMarkets Share Trading
AUD $8
ASX shares
Limited-time offer: Get 10 free ASX trades ($0 brokerage) when you open a share trading account with ThinkMarkets before 31 December 2021(T&Cs apply). $8 flat fee brokerage for CHESS Sponsored ASX stocks (HIN ownership), plus free live stock price data on an easy to use mobile app.
Bell Direct Share Trading
AUD $15
ASX shares, mFunds, ETFs
Finder Exclusive: Get 5 free stock trades and unlimited ETF trades until 31 Dec 2021, when you join Bell Direct. T&Cs apply.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Saxo Capital Markets (Classic account)
AUD $5
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.

Compare up to 4 providers

Is it a good time to buy Noxopharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Noxopharm price performance over time

Historical closes compared with the last close of A$0.43

1 week (2021-11-22) -10.42%
1 month (2021-10-29) -17.31%
3 months (2021-08-27) -25.22%
6 months (2021-05-28) -28.33%
1 year (2020-11-27) -32.28%
2 years (2019-11-29) 32.31%
3 years (2018-11-29) -21.82%
5 years (2016-11-29) -9.47%

Is Noxopharm under- or over-valued?

Valuing Noxopharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Noxopharm 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Noxopharm 's EBITDA

Noxopharm 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 million (£2 million).

The EBITDA is a measure of a Noxopharm 's overall financial performance and is widely used to measure a its profitability.

Noxopharm financials

Revenue TTM $5.6 million
Gross profit TTM $5.6 million
Return on assets TTM -26.86%
Return on equity TTM -34.84%
Profit margin -166.66%
Book value 0.141
Market capitalisation $125.7 million

TTM: trailing 12 months

Noxopharm share dividends

We're not expecting Noxopharm to pay a dividend over the next 12 months.

Noxopharm share price volatility

Over the last 12 months, Noxopharm 's shares have ranged in value from as little as $0.41 up to $0.99. A popular way to gauge a stock's volatility is its "beta".

NOX.AU volatility(beta: 0.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Noxopharm 's is 0.9616. This would suggest that Noxopharm 's shares are less volatile than average (for this exchange).

Noxopharm overview

Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock, as well as materials cooperative research and development agreement with the U.S. National Cancer Institute for treatment of brain cancer. The company was incorporated in 2015 and is based in Chatswood, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site